Synapse - Hematologic Malignancies Research

Results (3005)

Whole exome sequencing from nine independent sites of extraosseous disease in a single patient with relapsed multiple myeloma show that extramedullary disease arise through a combination of branched and parallel evolution

Meeting Abstract

Landau, H.; Fan, J.; Giralt, S. A.; Peled, J. U.; Hassoun, H.; Lesokhin, A. M.; Lendvai, N.; Korde, N. S.; Mailankody, S.; Chung, D. J.; more...
Blood (2016)

Fulltext@MSK | Save

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) followed by 2 years of lenalidomide maintenance (CRd-R): Updated results of a phase 2 study

Meeting Abstract

Kazandjian, D.; Korde, N. S.; Roschewski, M.; Mailankody, S.; Morrison, C.; Manasanch, E. E.; Kwok, M. L.; Tageja, N.; Bhutani, M.; Zingone, A.; more...
Blood (2016)

Fulltext@MSK | Save

Longitudinal (18)f-FDG-PET-CT analysis in newly diagnosed multiple myeloma (NDMM) patients following carfilzomib, lenalidomide, dexamethasone induction and lenalidomide maintenance (CRd-R)

Meeting Abstract

Korde, N. S.; Kazandjian, D.; Roschewski, M.; Mailankody, S.; Hultcrantz, M.; Yuan, C. M.; Stetler-Stevenson, M.; Choyke, P.; Hassoun, H.; Lesokhin, A. M.; more...
Blood (2016)

Fulltext@MSK | Save

The impact of prior malignancies on second malignancies and survival in MM patients: A population-based study

Meeting Abstract

Jonsdottir, G.; Lund, S. H.; Björkholm, M.; Turesson, I.; Wahlin, A.; Hultcrantz, M.; Porwit, A.; Landgren, O.; Kristinsson, S. Y.
Blood (2016)

Fulltext@MSK | Save

Phase I trial of targeted alpha-particle therapy with Actinium-225 ((225)Ac)-lintuzumab and low-dose cytarabine (LDAC) in patients age 60 or older with untreated acute myeloid leukemia (AML)

Meeting Abstract

Jurcic, J. G.; Levy, M. Y.; Park, J. H.; Ravandi, F.; Perl, A. E.; Pagel, J. M.; Smith, B. D.; Estey, E. H.; Kantarjian, H.; Cicic, D.; more...
Blood (2016)

Fulltext@MSK | Save

Sustained high rates of complete response and minimal residual disease negativity after 8 cycles of carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) followed by 2 years of lenalidomide maintenance (CRd-R) in patients with high-risk smoldering multiple myeloma: Updated results of clinical and correlative phase 2 study

Meeting Abstract

Kazandjian, D.; Korde, N. S.; Roschewski, M.; Mailankody, S.; Morrison, C.; Manasanch, E. E.; Kwok, M. L.; Tageja, N.; Bhutani, M.; Zingone, A.; more...
Blood (2016)

Fulltext@MSK | Save

Comparison of standard assays (serum immunofixation and protein electrophoresis) with Hevylite assay in patients with multiple myeloma

Meeting Abstract

Hassoun, H.; Ruiz, R.; Kazunori, M.; Azzi, K.; Devlin, S.; Cooper, B.; Lendvai, N.; Landau, H.; Lesokhin, A. M.; Chung, D. J.; more...
Blood (2016)

Fulltext@MSK | Save

Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy

Meeting Abstract

Hassoun, H.; Roshal, M.; Sabari, J.; Cooper, B.; Nguyen, J.; Ruiz, R.; Gao, Q.; Landau, H.; Lendvai, N.; Chung, D. J.; more...
Blood (2016)

Fulltext@MSK | Save

Pilot study of prognostic impact of pre-allogeneic hematopoietic cell transplantation (HCT) plasma levels of CXC-chemokines (CXCL-4 and CXCL-7) in patients with myelodysplastic syndromes (MDS)

Meeting Abstract

Dhakal, B.; Wang, T.; Haagenson, M. D.; Zhu, F.; Keever-Taylor, C. A.; Spellman, S. R.; Verneris, M. R.; Hsu, K. C.; Fleischhauer, K.; Lee, S. J.; more...
Blood (2016)

Fulltext@MSK | Save

A phase 1b study investigating carfilzomib administered once weekly in combination with lenalidomide and dexamethasone in patients with multiple myeloma

Meeting Abstract

Biran, N.; Siegel, D. S.; Berdeja, J. G.; Faber, E.; Seneviratne, L.; Alsina, M.; Bensinger, W.; Kimball, A. S.; Zhou, K.; Landgren, O.
Blood (2016)

Fulltext@MSK | Save